Effient Disease Interactions
There are 3 disease interactions with Effient (prasugrel).
Prasugrel (applies to Effient) bleeding
Major Potential Hazard, Moderate plausibility.
Prasugrel is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage, as this agent increases the risk of fatal bleeding.
References (1)
- (2009) "Product Information. Effient (prasugrel)." Lilly, Eli and Company
Prasugrel (applies to Effient) coronary and cerebral vascular disease
Major Potential Hazard, Moderate plausibility. Applicable conditions: Ischemic Heart Disease, Cerebrovascular Insufficiency
Prasugrel is contraindicated in patients with a history of prior transient ischemic attack (TIA) or stroke. Patients who experience a stroke or TIA while on prasugrel generally should have therapy discontinued. The risk of bleeding is increased in patients receiving prasugrel who undergo coronary artery bypass graft. If possible, prasugrel should be discontinued at least 7 days prior to the procedure.
References (1)
- (2009) "Product Information. Effient (prasugrel)." Lilly, Eli and Company
Prasugrel (applies to Effient) renal/liver disease
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
No dosage adjustment is necessary for patients with renal impairment. No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. Caution should be exercised in patients with end-stage renal disease and those with severe hepatic disease as such patients are generally at higher risk of bleeding.
References (1)
- (2009) "Product Information. Effient (prasugrel)." Lilly, Eli and Company
Switch to consumer interaction data
Effient drug interactions
There are 228 drug interactions with Effient (prasugrel).
Report options
More about Effient (prasugrel)
- Effient consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (21)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Generic availability
- FDA approval history
- Drug class: platelet aggregation inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Brilinta
Brilinta (ticagrelor) is used to lower your risk of having a stroke or serious heart problems after ...
Valsartan
Valsartan is an angiotensin II receptor blocker (ARB) that may be used to treat high blood pressure ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Plavix
Plavix (clopidogrel) is used to prevent blood clots after a recent heart attack or stroke. Includes ...
Warfarin
Warfarin is an anticoagulant used to prevent heart attacks, strokes, and blood clots. Learn about ...
Atenolol
Atenolol is used to treat angina (chest pain) and hypertension (high blood pressure). Learn about ...
Propranolol
Propranolol is a beta-blocker that is used to treat tremors, chest pain, high blood pressure, heart ...
Clopidogrel
Clopidogrel is used for acute coronary syndrome, acute coronary syndrome, prophylaxis, heart ...
Aspirin
Aspirin is used to treat mild to moderate pain and to reduce fever or inflammation. Learn about ...
Metoprolol
Metoprolol is used to treat angina (chest pain) and hypertension (high blood pressure). Learn about ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
